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MINUTES OF THE DRUG FORMULARY COMMISSION 
 
Meeting of August 6, 2015 
 
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH 
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DRUG FORMULARY COMMISSION 
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH 
Henry I. Bowditch Public Health Council Room, 2nd Floor 
250 Washington Street, Boston MA 
 
 
Docket: Thursday August 6, 2015 12:00 PM 
 
 
1. ROUTINE ITEMS: 
 
a. Welcome and Opening Remarks 
 
b. Introductions 
 
2. OFFICE OF GENERAL COUNSEL: 
 
a. Open Meeting Law 
 
b. Ethics & Conflict of Interest 
 
c. Quorum 
 
d. Remote Participation (Vote) 
 
3. OVERVIEW OF DRUG FORMULARY COMMISSION 
 
4. NEW BUSINESS: 
 
a. Discussion of Drug Formulary Commission’s Statutory Objectives 
 
b. Presentation and Discussion Regarding Opiates in Schedules II and III of the Massachusetts 
Controlled Substances Act 
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Drug Formulary Commission 
 
Presented below is a summary of the meeting, including time-keeping, attendance and votes cast.  
 
Date of Meeting: Thursday, August 6, 2015 
Beginning Time:  12:07 PM 
Ending Time:   1:53 PM 
Attendance and Summary of Votes:  
 
Board Member Attended Agenda Item 2d 
Dr. Douglas Brandoff Yes Yes Yes 
Cheryl Campbell Yes Yes Yes 
Ray Campbell III Yes Yes Yes 
Dr. Daniel Carr Yes Yes Yes 
Joanne Doyle-
Petrongolo 
Yes Yes Yes 
Stephen Feldman 
Yes Yes Yes 
Dr. Kenneth 
Freedman 
Yes Yes Yes 
Dr. Paul Jeffrey Yes Yes Yes 
Virginia Lemay Absent Absent Absent 
Eric Sheehan Yes Not voting Not voting 
Cindy Steinberg Yes Yes Yes 
Dr. Jeffrey Supko Yes Yes Yes 
Dr. Theoharis 
Theoharides 
Yes Yes  Yes  
Tammy Thomas Yes Yes Yes 
Summary 
13 
Members attended 
 
12 
Approved with votes 
 
12 
Approved with votes 
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PROCEEDINGS 
 
A regular meeting of the Drug Formulary Commission (M.G.L. Ch. 17, § 13) was held on Thursday, August 6, 2015 at the 
Massachusetts Department of Public Health, 250 Washington Street, Henry I. Bowditch Public Health Council Room, 2
nd
 Floor, 
Boston, Massachusetts 02108.  
 
Members present were:  Department of Public Health Interim Director of the Bureau of Health Care Safety and Quality, Eric 
Sheehan (Chair), Dr. Douglas Brandoff, Ms. Cheryl Campbell, Mr. Ray Campbell III, Dr. Daniel Carr, Dr. Joanne Doyle-Petrongolo, 
Mr. Stephen Feldman, Dr. Kenneth Freedman, Dr. Paul Jeffrey, Ms. Cindy Steinberg, Dr. Jeffrey Supko, Dr. Theoharis 
Theoharides and Ms. Tammy Thomas.   
 
Absent member was: Dr. Virginia Lemay. 
 
Also in attendance were the following staff from the Department of Public Health: Attorney Kay Doyle, Deputy General Counsel; 
Suzanne Cray, Director of the Office of Health Care Integration at the Bureau of Health Care Safety and Quality; Jonathan 
Mundy, Director of the Office of Prescription Monitoring and Drug Control at the Bureau of Health Care Safety and Quality; and 
David Dunn, Associate Executive Director of the Board of Registration in Pharmacy. 
 
Interim Director Sheehan called the meeting to order at 12:07 PM and made opening remarks before reviewing the agenda and 
introductions. 
 
Interim Director Sheehan stated that he was representing Department of Public Health Commissioner Dr. Monica Bharel and 
will serve as her representative as Chair of the Drug Formulary Commission.   Interim Director Sheehan explained that opioid 
abuse is a public health epidemic and the work before this Commission is critical to our efforts to develop solutions aimed at 
preventing and treating addiction.  He explained that Chapter 258 of the Acts of 2014 expanded the Commission’s mission, and 
the Commission is now tasked with preparing a drug formulary of interchangeable drug products for opioids that have a high 
chance of abuse and/or misuse.  To do this work, the Commission will consider the accessibility, cost and effectiveness of the 
substitute drugs.  Additionally, the Commission will review the drug’s abuse deterrent technology that could serve as an 
effective deterrent to abuse and misuse.   
 
Interim Director Sheehan asked if there were any changes to today’s agenda and asked for a motion to approve the agenda.  
Mr. Campbell made a motion to approve the agenda, and Dr. Theoharides seconded the motion.  All voted in favor of the 
agenda. 
 
Next, Interim Director Sheehan asked the members to introduce themselves.   
 
2. OFFICE OF THE GENERAL COUNSEL 
 
a. Open Meeting Law 
b. Ethics & Conflict of Interest 
c. Quorum 
d. Remote Participation (Vote) 
 
Attorney Kay Doyle provided a presentation on the Open Meeting Law, Quorum, and Remote Participation.   
Interim Director Sheehan asked if there was a motion to accept remote participation as an option for the Commission 
members.  Dr. Freedman made a motion to accept remote participation, and Mr. Feldman seconded the motion.  All voted in 
favor of remote participation. 
Attorney Doyle explained the need for members to complete Ethics and Conflict of Interest training.  The information to 
complete this training in PACE, the Commonwealth’s training system, will be sent to each member.  All training must be 
completed within 30 days of this meeting and a confirmation should be sent to the Department.  
3. OVERVIEW OF DRUG FORMULARY COMMISSION 
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Interim Director Sheehan stated that since it was the first meeting, it was important for each member to have an understanding 
of why we are here and the important work that we need to accomplish.  Jonathan Mundy, Director of the Office of 
Prescription Monitoring and Drug Control at the Department of Public Health, presented a brief overview of the Drug Formulary 
Commission and its statutory objectives, which is noted on the agenda under “New Business”. 
Mr. Mundy completed this presentation.  Interim Director Sheehan thanked Mr. Mundy for the presentation.  Interim Director 
Sheehan opened up the floor for questions. 
Dr. Theoharides asked if this was a new Commission to look at opiates or if it was the same as the previous Drug Formulary 
Commission.  Interim Director Sheehan responded that it was the same with an enhanced mission from Chapter 258 to look at 
Schedule II and III opiates. 
Dr. Freedman asked if the purpose was to concentrate on opiates used as medications or are we looking at how they are being 
used?  Mr. Mundy responded that we are going to look at how all the opiates are being used. 
Mr. Feldman stated that it would be useful to know what data is available through the Prescription Monitoring Program (PMP) 
including if refills are captured. 
Interim Director Sheehan gave an update on the status of the new online PMP system, including that the RFR will close on 
August 17.   
Dr. Theoharides stated that this will be a cumbersome process that carries a lot of legal implications.  We will need assistance 
from the Department’s legal staff.  Will the Commission members be covered if there is a lawsuit?  That will need to be 
mandatory for us to do our work.  Attorney Doyle stated that there is protection and it can be addressed at a future meeting. 
Dr. Carr noted that he would interpret equivalence from the patient perspective.  A certain opiate may work for a patient but 
the formulary states that another one fits.  Are we diminishing choices because of a pharmacological perspective?  He wished 
to make the application of the Formulary operational and practical.  
Dr. Theoharides stated that pharmacological and clinical substitutions are one side of it but there is also the individual patient 
that needs to be considered.   There are four categories for consideration: 1) pharmacologic substitution; 2) clinical 
substitutions; 3) individual patient and the variance of the impact of drugs on each person; 4) make up of the enzymes in the 
liver that breakdown this product. Patient samples can be analyzed to determine whether they do or do not have the ‘right’ 
enzymes that allow these opioids to either be metabolized (broken down) or be allowed to stay at higher concentrations. These 
factors can vary tremendously from patient to patient. This enters only into individual clinical practice but makes a significant 
difference to individual patients. 
 
 Dr. Brandoff stated that there are variations within one patient, depending on the status of the disease and metabolism.  Intra-
individual capability is important.  From a clinical point, how clinicians prescribe and what tools are available when prescribing 
are equally important considerations. Education of prescribers is important - is that within the Commission’s scope and 
purview?   
 
Interim Director Sheehan responded that we are working on promulgating regulation as part of the FY16 budget to change the 
requirements for pharmacists to input data into the PMP within 24 hours. We will also ensure PMP data is available for 
clinicians. 
 
Mr. Feldman commented that we should consider this in light of electronic health records and the availability of health data. He 
stated he is personally aware of one drug which requires diagnosis (for prescription by pharmacists). Otherwise a pharmacist 
doesn’t have diagnostic information or know what the drugs are for. Need to know what is being used to treat addiction in this 
case. 
 
Ms. Steinberg stated that in Massachusetts there is a requirement that every 2 years, physicians must take 3 hours of CEU in 
pain management including opioid prescribing. We may want to make a recommendation for training to be provided to 
educate pharmacists and other prescribers in this area. 
 
Mr. Supko asked what is the first goal for this Commission? What is the agenda/timeline? 
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Interim Director Sheehan responded stating that our goal is to develop a draft Formulary by early winter. The frequency of 
meetings from hereon in needs to be discussed. We also need to know what information the Commission members need from 
the DPH to make decisions. 
 
Mr. Supko asked what is the real objective? To look at the chemical entity of all the drugs and make recommendations for 
substitutions for everything on the list?   Interim Director Sheehan responded to say that is the expectation of the Commission 
and Mr. Dunn noted that our first step will be to look the drugs with the greatest abuse potential. 
 
Dr. Freedman asked how “concern” should be defined? Abuse or misuse on the basis of what data?   He also stated that the 
Commission will need to have the following data: 
 For the past 1-2 years, the number of individuals who died of drug overdose and how many had prescriptions of 
Schedule II and III prescription drugs. Means to potentially identify frequency and combinations. 
 Regarding PMP data, would like to see data on high utilizers, defined as seeing >4 physicians or pharmacists in the 
same year. We would want to know what such individuals are being prescribed. 
 Within the PMP there is not a requirement to report on the prescribing to patients receiving drugs for addiction, such 
as methadone.   
 
Ms. Steinberg stated that she would like to know if we collect data about overdoses including what drugs are in the individual’s 
system. Mr. Mundy responded that we can obtain that information. 
 
Dr. Freedman noted that even if we don’t have information for Massachusetts, comparable data from other States as well as 
national data would be useful. 
 
Mr. Feldman asked what is on the table for consideration by the Commission and what isn’t.  The way that prescriptions are 
filled could be looked at.   
 
Dr. Doyle-Petrongolo stated that access is an issue for patients. We should look at the barriers for obtaining prescription drugs. 
Regarding the timeframe, when is the timeframe in winter, because winter is long.  Interim Director Sheehan responded that 
our goal is to produce a draft by early winter. 
 
Mr. Campbell asked if there any resources available to the Drug Formulary Commission – if we thought other experts would be 
helpful.  Or is it just the members of this Commission?  Interim Director Sheehan responded by saying that we will follow-up on 
the consideration of external experts, but the intention is for DPH staff to be available too.   
 
Dr. Jeffrey asked what products are considered to be abuse deterrent or near abuse deterrent?  We will need a strategy for 
determining which drugs are high risk.  Some are a high likelihood for abuse but we will need guidance on what we should 
substitute with.   
 
Dr. Theoharides stated that we have such a diverse background, we need to compile list which will be difficult. A document 
listing different drugs and deterrents, given equivalence and given the abuse potential, would be helpful to provide a starting 
point. They do not all have the same therapeutic or biological equivalence. Some may be equivalent in terms of one aspect 
(abuse potential) but not in terms of another (therapeutic properties). 
 
Dr. Carr commented that the word “equivalence” is often expressed in pharmacological terms which is a bottom up approach. 
We may want to consider a top-down approach to assessing risk and take a departure from the current approach.   
 
4. NEW BUSINESS 
Interim Director Sheehan asked the commission members to comment on the potential barriers to meeting our goal that you 
see in your respective fields.   
 
Dr. Brandoff commented that all drugs have abuse potential, it’s more the medium in which they are prescribed that is 
important. He suggested we need a denominator to use to determine the scope and which drugs are taken in an abusive way 
and how many are taken as intended.  We need continued access for those who take the medication as intended.  
 
Interim Director Sheehan stated that an important role of the Drug Formulary Commission is to categorize abuse deterrence – 
that does not mean abuse proof. We will look at everyone’s expertise to educate and train the public. 
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Dr. Doyle-Petrongolo commented that we should consider quantities of what is being prescribed. We need guidelines for what 
is being prescribed for doctors.    
 
Mr. Campbell noted that lots of data is being discussed.  I hope we can make it part of our mission to educate the public. 
Providing context around data and understanding the privacy concerns of certain data requests can be very helpful.  Also, do 
we have the ability to get data from CHIA?  Interim Director Sheehan responded stating that we are looking at ways to get data 
out more effectively and will follow-up on obtaining data from CHIA. 
 
Dr. Carr stated that Blue Cross/Blue Shield had an advisory panel on guidelines for prescription of opioids post-surgery. He 
stated that he will submit those as reference.   
 
Dr. Jeffrey commented that we want to understand our task. Is it correct that we need to produce a document with lists of 
drugs to be published with the intention of directing pharmacists to substitute drugs? I want to confirm that is what we are 
about. Did I describe our task correctly?  Interim Director Sheehan responded by saying that was a good summary of our 
charge. I am aware this is a lot of work. My goal as Chair is to ensure I provide enough data and information to complete this 
work.  
 
Mr. Feldman noted that we will need evidence to back-up what drugs are put on the lists.  
 
Dr. Brandoff asked if Interim Director Sheehan could talk about the logistics of the meetings and expectations.   
 
Interim Director Sheehan responded by recommending a meeting of the Drug Formulary Commission on the first Thursday of 
every month moving forward and that meetings take place for three hours. Are there any thoughts from the Commission 
members on this recommendation? 
 
Dr. Theoharides asked if there could be sub-committees? I don’t think we can get this done meeting once a month.  Mr. Dunn 
responded stating that the Board of Pharmacy has subcommittees which have broken down into separate topics, some meet 
more frequently than others.  Interim Director Sheehan stated that we will discuss this further at the next meeting.  
 
Dr. Freedman stated that he preferred meetings to take place first thing in the morning or last thing in the afternoon.  Dr. 
Doyle-Petrongolo agreed.  Interim Director Sheehan responded stating that Mr. Mundy would send options out for the next 
meeting. 
 
Dr. Carr commented about equivalence – using the example of Oxycodone, hypothetically lots of different ones get swept 
under this generic category: oxycodone hydrochloride. Will our charge be to look at the different ones and say “this person 
wouldn’t necessarily need Oxycodone for that – that can be replaced with what we deem to be an equivalent amount of 
morphine”?  Mr. Mundy responded stating that we will get information that is needed – through literature searches and other 
State programs.  
 
Interim Director Sheehan asked the members if Commission members could provide us with guidance on what challenges have 
been experienced or foreseen potential barriers to completing this task ahead of us. 
 
Mr. Feldman stated that the biggest challenge is with patients – patients need pain medication first. How will the list be 
implemented?  
 
Dr. Doyle-Petrongolo commented that we know that we need to do a list but can we think about an algorithm? The pharmacist 
is likely to get caught in the middle. Mr. Dunn responded that we will research that approach. 
 
Interim Director Sheehan stated that the statute requires four things to be taken into consideration: effectiveness/efficacy of 
the drug, access, cost and effectiveness of the abuse-deterrence program.  Mr. Mundy commented that our process will be 
similar to a formulary developed in a hospital setting, but different to meet our needs.   
 
Mr. Feldman asked if we will have a preferred list of substitutes or will it be a “cannot use” list? Mr. Mundy stated that we will 
review and get back to the Commission on that question.  
 
Dr. Carr asked if the work related to the Commission has been completed previously by an insurer, other state, etc. Mr. Mundy 
responded stating that we don’t know but will research and get back to the Commission.  
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Mr. Feldman asked if hospital formularies are different than insurer formularies.  We need to consider the differences. 
 
Dr. Theoharides asked how the Commission should communicate if we want to help staff.  We have data that can be helpful.  
Attorney Doyle responded saying that all information should be submitted to Mr. Mundy and staff will determine how to 
distribute. 
 
Ms. Steinberg noted that she would like to have clarification around the language in the statute and in the charge.   
 
Interim Director Sheehan noted that our next steps are: 
 Email the members with dates for the next meeting. 
 Members need to sign the acknowledgment of receipt of the Open Meeting Law Guide and submit to staff. 
 You will get a handout on Ethics training.  Once completed, please send your certification to staff.   
                    
Interim Director Sheehan asked for a motion to adjourn.  Dr. Supko made the motion to adjourn and Mr. Feldman seconded.   
 
The meeting adjourned at 1:55 PM on a motion by and passed unanimously without discussion.  
 
  
LIST OF DOCUMENTS PRESENTED TO THE DRUG FORMULARY COMMISSION FOR THIS MEETING: 
1. Docket of the meeting. 
2. Copies of all power point presentations (emailed upon conclusion of the meeting). 
3. Copies of the August 3, 2015, press release on the Commission. 
4. Copies of the Attorney General’s Open Meeting Law Guide and instructions on how to access PACE for Ethics and Conflict 
of Interest training. 
5. Reimbursement information. 
 
 
Interim Director Eric Sheehan, Chair  
 
 
